Alnylam Pharmaceuticals (ALNY) Earnings Date, Estimates & Call Transcripts $245.44 +6.57 (+2.75%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Alnylam Pharmaceuticals Latest Earnings SummaryLatest Q3 2024 Earnings DateOct. 31ConfirmedActual EPS (Oct. 31) -$0.87 Missed By -$0.36 Consensus EPS (Oct. 31) -$0.51 Alnylam Pharmaceuticals posted Q3 2024 earnings on October 31, 2024, reporting an EPS of -$0.87, which missed the consensus estimate of -$0.51 by $0.36. Quarterly revenue fell 33.3% year-over-year to $500.90 million, below analysts' expectations of $532.91 million. With a trailing EPS of -$2.62, Alnylam Pharmaceuticals' earnings are expected to grow next year, from ($2.21) to ($2.07) per share. Conference CallConference Call TranscriptEarnings Press ReleaseEarnings Slide DeckSEC 10-Q/10-K FilingPowered by Get Alnylam Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alnylam Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataALNY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALNY Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Alnylam Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244-$1.26-$0.70-$1.02Q2 20244-$1.38-$0.90-$1.13Q3 20244-$1.12-$0.91-$1.02Q4 20244-$1.85-$0.71-$1.17FY 202416-$5.61-$3.22-$4.35Q1 20252-$0.95-$0.76-$0.86Q2 20252-$0.96-$0.74-$0.85Q3 20252-$0.82$0.15-$0.34Q4 20252-$0.53$0.01-$0.26FY 20258-$3.26-$1.34-$2.30Q1 20261$0.33$0.33$0.33Q2 20261$0.09$0.09$0.09Q3 20261$0.64$0.64$0.64 Alnylam Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails10/31/2024Q3 2024-$0.51-$0.87 -$0.36-$0.87$532.91M$500.90M8/1/2024Q2 2024-$0.74-$0.13+$0.61-$0.13$447.22M$659.83M5/2/2024Q1 2024-$0.75-$0.52+$0.23-$0.52$428.01M$494.33M2/15/2024Q4 2023-$1.20-$1.10+$0.10-$1.10$439.38M$439.72M11/2/2023Q3 2023-$1.61$1.15+$2.76$1.15$406.14M$750.53M8/3/2023Q2 2023-$1.72-$2.21 -$0.49-$2.21$331.73M$318.75MCrypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem5/4/2023Q1 2023-$1.97-$1.40+$0.57-$1.40$312.53M$319.29M2/23/2023Q4 2022-$2.13-$1.68+$0.45-$1.68$312.45M$335.04M Alnylam Pharmaceuticals Earnings - Frequently Asked Questions When did Alnylam Pharmaceuticals announce their last quarterly earnings? Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earning data on Thursday, October 31, 2024. Learn more on ALNY's earnings history. What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Alnylam Pharmaceuticals issued an update on its FY 2024 earnings guidance on Thursday, October, 31st. The company issued revenue guidance of $2.2 billion-$2.3 billion, compared to the consensus revenue estimate of $2.2 billion. Did Alnylam Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) missed the analysts' consensus estimate of ($0.51) by $0.36 with a reported earnings per share (EPS) of ($0.87). Learn more on analysts' earnings estimate vs. ALNY's actual earnings. How can I listen to Alnylam Pharmaceuticals's earnings conference call? The conference call for Alnylam Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Alnylam Pharmaceuticals's conference call transcript? The conference call transcript for Alnylam Pharmaceuticals's latest earnings report can be read online. Read Transcript How can I view Alnylam Pharmaceuticals's earnings report? Alnylam Pharmaceuticals's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Alnylam Pharmaceuticals generate each year? Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded annual revenue of $2.09 billion. How much profit does Alnylam Pharmaceuticals generate each year? Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded net income of -$440.24 million. ALNY has generated -$2.62 earnings per share over the last four quarters. What is Alnylam Pharmaceuticals's EPS forecast for next year? Alnylam Pharmaceuticals's earnings are expected to grow from ($2.21) per share to ($2.07) per share in the next year. More Earnings Resources from MarketBeat Related Companies Vertex Pharmaceuticals Earnings Date Gilead Sciences Earnings Date Regeneron Pharmaceuticals Earnings Date Biogen Earnings Date United Therapeutics Earnings Date Neurocrine Biosciences Earnings Date Incyte Earnings Date BioMarin Pharmaceutical Earnings Date Exact Sciences Earnings Date Exelixis Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover This page (NASDAQ:ALNY) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALNY Stock Alerts